Hi [[ session.user.profile.firstName ]]

Forensic Science

  • The devil’s in the e-detail: what HCPs really want from you
    The devil’s in the e-detail: what HCPs really want from you
    Heiko Schmidt, Integrated Multichannel Marketing and Sales, Bayer, Sari Ruth Carter, Head of Marketing, Anthill Agency Recorded: Dec 6 2018 68 mins
    Overview:
    Communication; we all do it, it is a critical part of effective business practice and in this pharma is no exception.

    It is no secret that for pharma companies, face time with healthcare professionals (HCPs) has reduced drastically over the last 10 years while the cost of in person engagements has increased significantly.

    Like any customer their expectations for the content they receive have changed, with a focus on useful, succinct and easy to consume materials rather than the sales materials of old.

    So what is it that HCPs want and through this lens, what is it that pharma should be doing?

    The evidence points towards creating meaningful two-way conversations through multiple channels, connecting otherwise siloed touchpoints with and for HCPs in the process.

    For the past 40 years detailing has been the backbone of pharma/HCP communication – but what about e-Detailing? Is it just detailing on an ipad or is it supposed to be something more? How does this fit and what is possible, and more importantly desirable?

    To analyse the current situation and present practical insights, pharmaphorum presents a new free to attend digital debate. Working with our partner Anthill agency we have put together a panel of leading experts from Bayer and Anthill.

    This debate will cover:

    •What is the current landscape for optimal HCP communication?
    •What is the future in terms of HCP channel preference?
    •New technologies in pharma marketing that help you to better engage with HCPs and extend HCP reach – AI, chatbots, self-detailing
    •How to reach more HCPs, when, where and how they want
    •How to overcome low content usage by HCPs
    •The most common challenges for traditional eDetailing effectiveness
    •How to achieve better communication without having to reinvent the wheel
    •How to activate your existing content and reach all customers willing to engage with your brand, regardless of their preference.
  • Can simulated datasets unlock the potential of patient data?
    Can simulated datasets unlock the potential of patient data?
    Jem Rashbass, Health Data Insight, Chris Carrigan, use MY data, Adam Reich, IQVIA, Dominic Tyer, pharmaphorum Recorded: Nov 27 2018 68 mins
    Patient level data offers the promise of insights which can craft new and better pathways, enable development of innovative therapies and treatments, and of course identify and prevent diseases much earlier in their lifecycle.

    One area of particular interest is cancer. However, in trying to realise the potential, the health sector is faced with the conundrum of protecting patients’ identities, while at the same time allowing doctors access to their data and enabling industry to benefit from vital insights into the disease.

    This presents a paradox, as the UK has some of the best healthcare data in the world, however, accessing the data can be challenging and time consuming due to patient confidentiality checks.

    So, what is the solution?

    IQVIA brings a unique perspective to this event, having partnered with Health Data Insight to develop an innovative solution to this seemingly intractable problem: Simulacrum, a database comprised of only artificial data that is modelled on real patient data collected by the National Cancer Registration and Analysis Service (NCRAS) in England.

    Simulacrum has already produced identical results to the real data when predicting incidence of tumours in the population, whilst simultaneously removing any risk of breaching patient confidentiality.

    In this webinar, IQVIA and pharmaphorum will also provide advice to industry, patient advocacy groups and healthcare professionals on how to leverage Simulacrum, and utilise this simulated dataset to facilitate access to England’s world-leading healthcare data, while complying with regulations designed to protect and maintain individual confidentiality.
  • Digital therapeutics and healthcare innovation
    Digital therapeutics and healthcare innovation
    Roberto Ascione, Healthware International, Megan Coder, Digital Therapeutics Alliance, Pierre Leurent, Voluntis Recorded: Oct 12 2018 70 mins
    Digital technology is transforming the way that healthcare is practiced and delivered, with areas like digital therapeutics forging ahead to complement traditional medical approaches and augment patient care.

    The development of software applications that are available with a prescription took a major step forward last year with the first FDA approval for a mobile medical application with both a safety and efficacy label.

    At the same time as digital therapeutics are breaking new ground there’s a whole ecosystem of digital health innovations that are also tackling healthcare issues in new and imaginative ways.

    From doctor-patient communication to managing healthcare costs, from healthcare monitoring to clinician workflow, the range of digital health tools and services available is rapidly expanding.

    We’ll be looking at how digital and traditional approaches to medicine are being combined to improve patient outcomes.

    This free webinar will also see our expert panel:
    •Consider the current state of play with digital therapeutics and what the future holds for them
    •Discuss how to harness healthcare innovations to involve and engage patients
  • Realising the biotech promise: addressing the path to market
    Realising the biotech promise: addressing the path to market
    Steve Bates, BIA, Sheela Upadhyaya, NICE, Fred Jacobs, TYG, Dean Summerfield, IQVIA Recorded: Oct 9 2018 72 mins
    Now more than ever before, Biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.

    The journey from molecule discovery and development through valuation, funding, regulatory and commercialisation can be a long and complex road to travel though.

    These companies have to navigate a rapidly changing and increasingly complex landscape from pre-clinical valuation through foresight and planning at every stage of the asset life cycle - and at a time when Brexit adds uncertainty about regulatory approval and launch windows.

    Working with IQVIA, pharmaphorum has assembled a specialist panel to discuss these challenges and the most effective routes to overcoming them.

    On Tuesday 9th October at 15:00 BST / 10:00 EST we will present a free-to-attend online debate which will bring these experts together to deliver insight on topics such as market valuation, financing, navigating regulatory hurdles, patient engagement & HTA strategies through to successful commercialisation.
  • A full overview of different technologies to increase HPLC efficiency & speed
    A full overview of different technologies to increase HPLC efficiency & speed
    Dr. Frank Michel, Analytical & Chromatography Scientific Advisor, Merck KGaA, Darmstadt, Germany Recorded: Oct 4 2018 64 mins
    In the recent decades the demand for higher separation efficiency or higher speed in HPLC has increased strongly. The response to this demand was answered by modern HPLC technologies such as UHPLC with sub-2 µm particles, monolithic silica or Fused-Core™ particles. This webinar provides an overview on the factors that influence the speed of the HPLC method. It introduces the different approaches of small HPLC particles, Fused-Core (also known as core-shell) particle technology and monolithic silica rods and discusses the advantages and disadvantages of each approach. The presentation covers the theoretical background of these technologies and multiple examples of applications.
  • 爱思唯尔卓越科研在线讲座:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    爱思唯尔卓越科研在线讲座:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    Helena Wang Recorded: Sep 6 2018 64 mins
    与《柳叶刀》亚洲区执行主编王辉(Helena Wang)女士一起学习在高影响力期刊上发表论文的技巧和策略。王辉女士将分享她在整个研究论文发表周期中与研究人员和论文作者合作的经验,介绍如何撰写能够在优质出版物上发表的论文,以及广泛传播研究成果的机会。本次在线研讨会内容精彩纷呈,不容错过,能够让您的研究过程和研究影响再上新台阶。This webinar will be in Mandarin (Chinese).
  • Engaging with HCPS: what do HCPs want from medical meetings?
    Engaging with HCPS: what do HCPs want from medical meetings?
    Aoife Delmas, European Society of Cardiology, Katie Koziol and Andrew Moore, Ashfield Meetings & Events Recorded: Jun 26 2018 65 mins
    There has been a myriad of reasons over the past few years to safely assume the popularity and perceived worth of face-to-face medical meetings was well and truly on the decline – from advances in technology, to funding challenges.

    Separate, yet complementary studies looking at global HCP preferences reveals that the medical meeting is in fact their preferred channel for scientific communications.

    Yet a 2018 study by Ashfield looking at global HCP preferences reveals that the medical meeting is in fact their preferred channel for scientific communications.

    Furthermore, HCPs exhibit consumer behaviours in selecting and attending events – which means that while these conferences offer potential engagement riches, they have to offer a specific mix of focus, value and ROI to be successful. To analyse this situation, discuss the learnings from the research and offer guidance on what a modern medical meeting needs to be we present an exclusive debate.

    Bringing together experts from Ashfield Meetings & Events and the European Society of Cardiology our panel will discuss:

    1. Findings from the 2018 Ashfield Science of HCP Meetings research and whitepaper
    2. How HCPs want to engage with pharma and scientific communications
    3. What works? How to create the events that HCPs want to attend
    4. The future of meetings - balancing face to face and digital
    5. How HCPs determine whether a meeting is likely to be worth the investment
    6. Strategies and tactics for planners and meeting stakeholders to implement to continue to add value for HCPs attending medical meetings
  • User Profiles Tutorial
    User Profiles Tutorial
    Kathleen Berryman Recorded: Jun 18 2018 4 mins
    A short tutorial showing how to create and use the user profiles feature in Cabells.
  • Calls for Papers Tutorial
    Calls for Papers Tutorial
    Kathleen Berryman Recorded: Jun 10 2018 2 mins
    A short tutorial showing the calls for papers feature in Cabells Whitelist
  • Cabells Metrics Tutorial
    Cabells Metrics Tutorial
    Kathleen Berryman Recorded: Jun 10 2018 6 mins
    A short tutorial on what metrics Cabells offers and what each one means.
  • Custom Assay Development & Services utilizing Single Molecule Counting (SMC™)2
    Custom Assay Development & Services utilizing Single Molecule Counting (SMC™)2
    Sarah Hamren, Head of Custom Assays & Sample Testing, Merck KGaA, Darmstadt, Germany Recorded: May 24 2018 36 mins
    Single molecule counting (SMC™) technology enables precise measurement of molecules at levels previously undetectable, down to the femtogram/mL levels, allowing researchers to identify new biomarkers, or assist in therapeutic development with an improved view of efficacy, safety & time course studies. When time and resources are limited, Merck KGaA offers a comprehensive portfolio of Custom Services supported by a scientific team with core expertise in SMC™ technology. Learn how our team will partner with you to develop a project specific to your requirements, whether that is fit-for-purpose sample testing, biomarker analysis using our current SMC™ immunoassays, or development and manufacture of an immunoassay for your novel target of interest. Learn how we work with our clients to define and tailor a customized project plan that includes milestone driven tasks, collaborative data review and progress reports. Whether your focus is to expedite your clinical research or to transfer a method to a CRO, we will show you how our services can help you accelerate programs from discovery into clinical trials.
  • Custom Assay Development and Services utilizing Single Molecule Counting (SMC™)
    Custom Assay Development and Services utilizing Single Molecule Counting (SMC™)
    Sarah Hamren, Head of Custom Assays & Sample Testing, Merck KGaA, Darmstadt, Germany Recorded: May 23 2018 32 mins
    Single molecule counting (SMC™) technology enables precise measurement of molecules at levels previously undetectable, down to the femtogram/mL levels, allowing researchers to identify new biomarkers, or assist in therapeutic development with an improved view of efficacy, safety & time course studies. When time and resources are limited, Merck KGaA offers a comprehensive portfolio of Custom Services supported by a scientific team with core expertise in SMC™ technology. Learn how our team will partner with you to develop a project specific to your requirements, whether that is fit-for-purpose sample testing, biomarker analysis using our current SMC™ immunoassays, or development and manufacture of an immunoassay for your novel target of interest. Learn how we work with our clients to define and tailor a customized project plan that includes milestone driven tasks, collaborative data review and progress reports. Whether your focus is to expedite your clinical research or to transfer a method to a CRO, we will show you how our services can help you accelerate programs from discovery into clinical trials.
  • Systematic searching with Emtree
    Systematic searching with Emtree
    Embase Customer Care Representative: Dr. Josephine Zimmermann Recorded: May 23 2018 52 mins
    Embase wouldn’t be Embase without Emtree, the life science thesaurus is a hierarchically structured, controlled vocabulary, for Biomedicine and related Life Sciences, providing a consistent description for Embase indexing.

    - It offers indexers a comprehensive vocabulary to describe the content of biomedical data;
    - For database users, it facilitates comprehensive searching and high precision retrieval.

    Emtree has been used to index Embase (including Embase Classic) since 1947, and is unrivalled in its coverage of drug and medical terminology.

    In this webinar, Embase Customer Care Representative Dr. Josephine Zimmermann will walk you through:

    - How Emtree is built-up and managed
    - How we index a typical article
    - How drugs, diseases and devices are indexed in Embase

    About the speaker:
    Josephine Zimmermann holds a PhD in Molecular and Structural Chemistry and Physics from University of Grenoble for her research on the synthesis of fluorescent core-shell nanoparticles for medical imaging. Since two years, she works as Customer Care Representative at Elsevier and supports Embase as well as other Life Science Products. She is reporting the voice of the customer by collaborating closely with the Embase team, analyzing tendencies, providing feedback, and helping you with any kind of issues.
  • Shine a Spotlight on your Institutional Research
    Shine a Spotlight on your Institutional Research
    Thought Leaders - Traci Grodner and Curtis Maggard Recorded: May 22 2018 30 mins
    If you are a researcher, a department dean at a prestigious university or a librarian looking for research tools to help researcher and faculty members save time and create new research faster; you won't want to miss this informative webcast. We invite you to join us on May 22 at 11:00a.m. EDT for our live webcast.

    With research influencing accreditation policies and overall student engagement, now is the time to accelerate your institution's data management plan. When it comes to managing scholarly research, there's a lot that goes into data collection, preservation, and idea sharing.

    Early-Stage Scholarly Research Gets Your Institution in the Spotlight: an introduction to early-stage scholarly research and the value of showcasing your researchers' fundamental ideas, concepts, working papers, in an open-sharing environment while increasing readership of your institution's and/or department's overall community engagement.
    You'll be pleased you tuned-in!
  • Reducing efficacy-related failures with PharmaPendium
    Reducing efficacy-related failures with PharmaPendium
    Sherry Winter, PhD Recorded: May 22 2018 49 mins
    Join us for this 45-minute webinar that will include in-depth information and demonstrations of how to leverage the comparative data in PharmaPendium to reduce the risk of late-stage failures. With a focus on efficacy, we will discuss how PharmaPendium enables you to:

    •find efficacy weaknesses early,
    •identify the most appropriate preclinical models,
    •improve success rates of Phase I and II clinical trial designs by optimising selection of sample size,
    •primary/secondary endpoint and study design and
    •prepare for more effective regulatory reviews
  • Identifying Drug-Drug Interactions using PharmaPendium
    Identifying Drug-Drug Interactions using PharmaPendium
    Sherry Winter, PhD Recorded: May 2 2018 57 mins
    * Note the change of date*
    Learn how to identify and assess drug-drug interactions with extracted pharmacokinetic, metabolising enzyme & transporter data and a powerful Drug-Drug Interaction risk calculator
  • Searching for drug safety and benefit-risk evaluations
    Searching for drug safety and benefit-risk evaluations
    Dr. Jean-Dominique Pierret, Scientific Information Expert Recorded: Apr 25 2018 56 mins
    Scientific literature is one of the largest source of adverse event reports, making it an essential part of pharmacovigilance. Marketing authorization holders are expected to perform systematic literature searches using reference databases and local journals from countries where the medicinal product has a marketing authorization. The retrieved information needs to be collated, analyzed, and communicated at least once a week. However, several challenges are associated with this process. Large amounts of data from various sources, various regulatory requirements, building and maintaining search strategies increase the complexity of literature searches.

    In this webinar, Scientific Information Expert Dr. Jean-Dominique Pierret will give a brief overview of regulatory obligations and usefulness of literature in the drug development process. And then he will introduce how he set up literature search for pharmacovigilance: such as selecting the databases, building the strategy with a focus on early detection of safety issue and benefit/risk assessment. Finally, he will give examples of challenges that may occur during literature search for pharmacovigilance.

    About the speaker:
    Dr. Jean-Dominique Pierret is a Scientific Information Expert and he spent +20 years in the pharmaceutical industry. He is currently working for Galderma R&D. With a strong background in information sciences applied to the biomedical domain, he is involved in the management of a corporate scientific library, in competitive intelligence and in information retrieval. Jean-Dominique is in charge for years of the literature survey for pharmacovigilance.
  • Digital health: how can technology be used to engage hard-to-reach patients?
    Digital health: how can technology be used to engage hard-to-reach patients?
    Trishna Bharadia, MS patient advocate, Jo Sopala, MS Trust, Rachel Morrison, NHS Western Isles Recorded: Apr 20 2018 65 mins
    Helping someone live with a condition as complex as MS can be fraught with challenges.

    MS professionals are asked to manage multiple physical and psychological symptoms while following complicated drug monitoring regimes, all in the face of shirking resources and growing caseloads.

    As the burden of monitoring people on disease modifying therapies has grown, a corresponding lack of resource for symptom management has led to inequity of services for those with progressive disease.
    Across the UK, however, technology is being used to overcome these obstacles, by erasing geographic boundaries and expanding access.

    From conducting video consultations to setting up online peer support groups, digital health can and is being utilised to improve services for everyone.

    As part of the Quality in the Delivery of Services (QuDoS) in MS recognition programme, a panel of experts will discuss how to meet the information, support and engagement needs of people living with MS through technology.

    The live webinar, produced by pharmaphorum with the support of the MS Trust and Biogen, will feature the views of patients and professionals alike.

    The panel, which will include Jo Sopala, Director of Development at the MS Trust, will discuss using digital health to:
    -Increase patient access to quality, trusted information through digital translation services
    -Offer greater support through online peer support and symptom management apps
    -Boost adherence through electronic reminder systems
    -Increase involvement in clinical trials through wearable technologies
    -Increase access to services through remote appointments
  • Embase for Medical Affairs
    Embase for Medical Affairs
    Embase Product Manager: Dr. Iveta Petrova Recorded: Apr 19 2018 47 mins
    Medical affairs teams need quick direct access to the latest literature so they can rapidly respond to client inquiries from anywhere. Embase has unique and comprehensive journal and conference coverage, in-depth indexing that makes it easy to find answers and customizable e-mail alerts that send out regular updates to automate the retrieval of information. Embase specialized capabilities ensure not only comprehensive retrieval of relevant information, but also that it is done in an easy and fast way saving time and money.

    In this session, Elsevier's product manager Dr. Iveta Petrova will demonstrate how Embase can support daily tasks, including:

    - How to design a comprehensive EBM search in just a few steps
    - How to follow innovations in your subject field and related KOLs
    - How to make an indirect comparison between two drugs
    - How to identify opportunities for an investigator initiated trial

    About the speaker:
    Iveta Petrova holds a Ph.D. from Leiden University for research done on Wnt signaling in the nervous system. For the last three years, she is part of the Embase team. Main focus is addressing specific use cases of Medical Affairs professionals by leveraging the capabilities and peer-reviewed enhanced content of the biomedical database Embase, as well as continuous engagement with customers and market research to further improve and develop tools to support them in their daily responsibilities.
  • Introduction to the Education Network - EduRN
    Introduction to the Education Network - EduRN
    Shirley Decker-Lucke Recorded: Apr 11 2018 33 mins
    You are invited to join the Education Research Network (EduRN) – the education community’s platform for sharing early-stage research, including preprints, working papers, and data prior to publication. EduRN is powered by SSRN, the leading working paper repository and preprint server since 1994.
  • Leverage PK data in PharmaPendium to inform drug development strategies
    Leverage PK data in PharmaPendium to inform drug development strategies
    Sherry Winter, PhD Recorded: Mar 27 2018 48 mins
    Pharmacokinetic information from FDA and EMA regulatory documents informs translational and clinical development decisions and may lead to more successful drug development and regulatory approval strategies.

    In this webinar, we will discuss how to leverage comparative pharmacokinetic information from FDA and EMA Drug Approval documents to make better-informed decisions on which drugs have the most potential to succeed in clinical development.
  • How To Publish in High Impact Journals
    How To Publish in High Impact Journals
    Cell Press Editor-in-Chief Robert Eagling and Dr. Rebecca Cooney, North American Executive Editor of The Lancet Recorded: Mar 27 2018 76 mins
    Join Dr. Robert Eagling, Cell Press Editor-in-Chief of Chem, and Dr. Rebecca Cooney, North American Executive Editor of The Lancet, to learn about techniques and strategies for authoring in high-impact journals. Dr. Eagling will present information on authoring with Cell Press, which includes such titles as Cell, Neuron, Chem, Immunity, Joule, and Cancer Cell. In addition, Dr. Cooney will represent publishing in The Lancet premium medical journal portfolio.


    The editors will present their experience working with researchers and authors throughout the research publishing cycle, how to develop papers for premium publications, and the opportunity to broadly disseminate findings. You won’t want to miss this engaging webinar and how it can benefit your research process and impact.
  • Finding the right information for Medical Device Clinical Evaluation and PMS
    Finding the right information for Medical Device Clinical Evaluation and PMS
    Embase Senior Product Manager: Dr. Ivan Krstic Recorded: Mar 21 2018 62 mins
    Information found in the biomedical literature is a significant source for every stage of the medical device life cycle, from concept and design through clinical trials to release and reimbursement, as well as post-market surveillance.

    In June 2016, the updated Medical Device Clinical Evaluation Report (CER) guidelines came into effect (Revision 4 of MEDDEV 2.7/1), detailing where and how to search for literature and how to record the process of collecting, appraising and analyzing the items found.

    In this session, Elsevier's senior product manager Dr. Ivan Krstic demonstrated how Embase is especially suited to help Medical Device manufacturers prepare CER, including:

    - How to design effective literature searches for Clinical Evaluation reports using the PICO search form in Embase;
    - How to build a more comprehensive search using Emtree terms and synonyms;
    - How trade name and manufacturer name indexing supports analyses of devices already on the market;
    - How to find mentions of adverse device reactions in the literature for effective post-market surveillance (PMS) reporting
  • Promoting Open Access Scholarship - SSRN & Bepress Digital Commons
    Promoting Open Access Scholarship - SSRN & Bepress Digital Commons
    Gregg Gordon Recorded: Mar 21 2018 34 mins
    Gregg Gordon, managing director at SSRN, answering questions for our RPS community about the synergies of SSRN and Bepress.
  • UK pharma and integrated health
    UK pharma and integrated health
    Stephen Dorrell, NHS Confederation, James Roach, Accountable Care Partnership, Essex Andrew Smith, Cobic, Steve Jowett, IQVIA Recorded: Mar 21 2018 64 mins
    The concept of integrated healthcare is not new to the UK, where it has been discussed since the late 1960s.

    The difference is that now it could really happen. Technology, medicine, regulation and pricing have all evolved to a point where a collaborative, integrated system is not only possible, but desirable – and the data needed for it to become a reality is now available.

    What does this mean for UK pharmaceutical companies that have historically focused on providing medicines and treatments?

    On one hand there are calls for them to change – going beyond being simply a supplier of products and moving into the role of partner, sharing risk to drive great health outcomes.

    On the other hand, the industry’s move into having pipelines that are largely stocked with niche products has created pricing and access questions which are yet to be fully answered.

    Analysing the current situation and looking for potential routes to the future, this high-level IQVIA/pharmaphorum webinar gave an update on the latest developments and debated how pharma can be a catalyst for change at a time when the NHS is under immense pressure to cut costs and become more efficient.

    Insight on these pressing issues was provided by a panel of influential healthcare experts that included former secretary of state for health, and NHS Confederation current chairman, Stephen Dorrell.

    He was joined by:
    James Roach, director, Accountable Care Partnership, West Essex Health and Care System
    Andrew Smith, director, Cobic
    Steve Jowett, country lead for health system engagement, IQVIA

    Watch the digital debate to learn more about:

    The evolving NHS and the STP/ICS model of delivery
    What a collaborative future could look like
    The role of data in the future NHS
    Why the STP/ICS model is important for pharma
  • Metrics to meaning: demonstrating the value of medical communications
    Metrics to meaning: demonstrating the value of medical communications
    Scott McGregor, Allergan, Lynda Chang, Complete HealthVizion, David Pearce, Complete HealthVizion, Dominic Tyer, pharmaphorum Jan 23 2019 3:00 pm UTC 75 mins
    Medical affairs and publications teams are under increasing pressure to demonstrate effectively the success of the medical communications activities they undertake.

    Naturally, there are a huge number of metrics that could be used to measure and demonstrate medical communications value. The challenge is to identify, and track, those metrics that really matter, and ensure this information is interpreted effectively.

    This pharmaphorum webinar, which will be held in partnership with Complete HealthVizion, will look at how to measure medical communications activities, how to continue with what is successful and how to change what isn’t working.

    This means identifying what can be measured, both in terms of reach and engagement as well as behavioural impact, deciding what ‘great’ looks like and how best to define success.

    The expert panel will also look at how behavioural science can provide a framework to develop smarter communications and, ultimately, drive better patient outcomes.

    This Metrics to Meaning webinar will take place on Wednesday, 23rd January, at 15:00 pm GMT (10:00 EST) and will teach you how to measure the effectiveness of different types of medical communications programmes.

    Interacting with the panel will also allow you to learn about a range of practical approaches to implementing metrics, including:

    • Innovative ways to measure medical communications value and success
    • How to help medical affairs and publications teams demonstrate greater value
    • How to optimise tactical outputs year on year
    • The importance of demonstrating and measuring behavioural change

    In doing so they will also discuss the role of behaviour and the implications of this for measuring success.
  • Cancer, genomics and personalised medicine: Modelling the future of oncology
    Cancer, genomics and personalised medicine: Modelling the future of oncology
    Danyi Wen, Shanghai LIDE Biotech, Stefan Jellbauer, Mitra Biotech, Lakshmi Santhosh Maithel, Repositi Jan 29 2019 4:00 pm UTC 75 mins
    The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in 2 people in the UK and 1 in 2 men/1 in 3 women in the US will experience it at some stage in their lives. And yet the picture for patients is an improving one.

    The move towards immunotherapies heralds much promise and this is potentially just the beginning. As cancer is understood increasingly not by type, or even tumour type but specific mutation the era of personalised oncological therapies is visible.
    To delve further into this pharmaphorum is pleased to present an exclusive online discussion.

    Bringing together experts at the cutting edge of this field it aims to interrogate where we are in terms of this shift towards personalised oncology, what this means in terms of the development pathway and looks at the approaches which could (and will) fully evolve the way that cancer treatments are developed in terms of efficacy, approach and outcome.

    this free to attend event will cover a number of topics critical to the future of oncology including:
    •The changing face of cancer: how do we define it now?
    •Personalised medicine in practice – where are we now in cancer?
    •What are the implications from these changes for clinical trials?
    •How the shift towards cancer as a phenotype/genotype is being applied in clinical trials and how they are run
    •What are co-clinical trials and why could they hold the key to answering unmet need in cancer treatment and beyond into broader drug development?
    •Modelling for the future of cancer – can this be done for personalised therapies?